Orangefiery, the firm that combines the rigor of strategy consulting with the real-world perspective of communications to help clients drive change, today announced the expansion of its C-suite with the appointments of Diana Dopfel as Chief Operating Officer and Laura Smith as Chief People Officer.
An interview with Orangefiery Best Master’s Thesis Award Winner Karen Robayo Sanchez on gender equity differences in PR in North and Latin America.
Orangefiery has been shortlisted for a PRWeek Healthcare Award in the Best in Health Innovation category for our rebranding work for Lyndra Therapeutics.
Journalism student Madi Willoughby writes about her experience as a PR intern at Orangefiery communications & consulting form in New York NY.
Orangefiery Communications interviews Best Master’s Thesis Award Winner Corinne Zilnicki on misinformation in times of crisis.
If you’re developing the marketing plan for a new, innovative product, consider using market development strategies to prime the market for growth.
Launching an innovative product is a fundamental challenge for many commercial and marketing leaders. Learn how to prime markets for growth with a successful market development strategy.
The cruise industry took a hard hit with the onset of COVID-19. Learn about the potential future of the cruise industry and what I learned from a six-night Royal Caribbean Oasis cruise.
Why “anti-vaxxers” have been able to share disinformation about COVID-19 and COVID-19 vaccination so widely on social media platforms.
Orangefiery is pleased to sponsor IPR’s Best Master’s Thesis of the Year Award, which recognizes and encourages graduate study and scholarship in public relations through an annual award for an outstanding Master’s thesis. Apply now!
As a college senior working towards a dual degree in public relations and policy studies, a part-time intern, and an account supervisor for SU’s on-campus PR firm, Hill Communications, the transition to working remotely in March 2020 was difficult. This is particularly true because one of my favorite things about being a college student is constantly being on the go.
In the last week, Pfizer/BioNTech and Moderna both announced results from two COVID-19 Phase 3 clinical trials showing efficacy of greater than 90 percent. According to company press releases, the trials showed no significant safety issues. (Full publication of the data is yet to come, as is standard practice.)
